DGAP-News: Biotest AG
/ Key word(s): Miscellaneous
15.09.2021 / 07:00
The issuer is solely responsible for the content of this announcement.
Biotest announces the new Renate & Hans Schleussner Award for scientific research
Dreieich, 15 September 2021. Biotest announced today that a new scientific award, the Renate & Hans Schleussner Award, which will be available and open for application from now on. The daughter from Renate & Hans, Cathrin Schleussner was a member of the Supervisory Board of “Biotest AG” since 2001 and held the position of Deputy Chairman from 2004 until the takeover by the Chinese “Creat Group” in 2018.
Immunoglobulins are a major component of the immune system. They are a potent natural tool to counteract viral and bacterial infections.
Scientists or clinicians with innovative ideas relevant to the prevention or treatment of viral infections with (hyper-) immunoglobulins are invited to submit their application. Projects should be related to pathology or management of the disease. Applicants must submit an original research contribution to basic or clinical research. Applications are encouraged from both individuals and teams conducting research at hospitals, universities or independent institutions.
Deadline for the submission of a first project concept is January 31st, 2022. Selected awardees will be invited to prepare a full project proposal. Details on how to apply for the award can be found at:
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1233268|
|End of News||DGAP News Service|